Clinical trials demonstrate that patients receiving liraglutide showed 18% slower cognitive decline over one year compared to placebo 30
That said, there could be some issues when it comes to distribution
followed by the one with the largest PRIMARYID value for reports with the same CASEID and FDA_DT
The American Diabetes Association (ADA) guidelines recommend GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes and atherosclerotic cardiovascular disease, while SGLT2 inhibitors are preferred for heart failure and chronic kidney disease
Patients experiencing metabolic concerns should consult their GP or practice nurse for evidence-based treatment options, which may include lifestyle modifications and NICE-recommended pharmacological interventions where appropriate
On mechanism, the peptides and the small molecules end up at the same destination (Gs activation, cAMP elevation, the canonical incretin pharmacology) but they get there via different binding modes and with different signalling profiles